BioSpace News Archive

Galera Therapeutics, Inc. (Nasdaq: GRTX) today presented data from the Phase 3 ROMAN trial demonstrating avasopasem manganese (avasopasem) improved preservation of kidney function and reduced cisplatin-related chronic kidney disease (CKD) in patients with head and neck cancer (HNC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

PDS Biotechnology Corporation announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, presented at the 2023 American Society for Clinical Oncology meeting.

Activ Surgical, a digital surgery pioneer, presented findings today at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting from a clinical study conducted at The Ohio State University Wexner Medical Center using the ActivPerfusion™ and ActivICG™ modes within its FDA cleared product, ActivSight™ Intelligent Light (ActivSight).

MEDSIR announced today the results of the PALMIRA trial.

Waters Corporation announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 58,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to seven newly hired employees.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.

Aravive, Inc. announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual Meeting being held on June 10th in Park City, Utah.

Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023 at 1:00 PM ET.